Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 8/2023

01.08.2023 | Research

Investigation and analysis of the comprehensive unmet needs of cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

verfasst von: Xiaoyan Luo, Renshan Cui, Ningning Zhang, Haiying Jiang, li Zhou, Xue Wang

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to describe the level of comprehensive needs among cancer patients treated with immune checkpoint inhibitors, to explore the relationship between comprehensive needs and demographic factors, and to examine the relationship between comprehensive needs and treatment variables.

Method

A cross-sectional descriptive study design was adopted. From September 2021 to July 2022, 194 cancer patients treated with immune checkpoint inhibitors were recruited using a convenience sampling method in tertiary teaching hospitals in Zhejiang Province, China. The Comprehensive Needs Assessment Tool for Cancer Patients (CNAT) and questionnaires to assess demographic and clinical characteristics were used to collect data.

Results

The average comprehensive needs score for cancer patients treated with immune checkpoint inhibitors was 39.2 ± 17.2. Patients reported high levels of medical care needs, knowledge information needs, hospital facilities needs and nursing needs but low levels of religious spiritual support needs, psychoemotional needs, actual support needs, and physical symptom needs. Multiple stepwise linear regression showed that age, primary caregivers, cancer type, number of immunotherapy courses and the occurrence of immune-related adverse events (irAEs) were the main factors affecting the comprehensive needs of cancer patients treated with ICIs (p < 0.05).

Conclusions

Age, primary caregivers, cancer type, number of immunotherapy treatment courses and the occurrence of irAEs are important factors affecting the comprehensive unmet needs of cancer patients treated with immune checkpoint inhibitors. Nurses should perform targeted interventions according to the different situations of patients to improve the quality of care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Hirsch L, Zitvogel L, Eggermont A, Marabelle A (2019) PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Can-cer 120(1):3–5CrossRef
2.
Hoos A (2016) Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discovery 15(4):235–247CrossRefPubMed
3.
SanmamedMF ChenLP (2019) A paradigm shift in cancer immuno-therapy: from enhancement to normalization. Cell 176(3):677CrossRef
4.
Zhao Jing Hu, Hanguang WS et al (2020) Advances in studies of immune checkpoint inhibitors in colorectal cancer. Journal of Practical Oncology 35(06):13–18
5.
Wrobel P, Ahmed S (2019) Current status of immunotherapy in metastatic colorectal cancer. Int J Color Dis 34(1):13–25CrossRef
6.
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168CrossRefPubMed
7.
Institute of Medicine (US) (2008) Committee on psychosocial services to cancer patients/Families in a community setting. In: Adler NE, Page AEK (eds) Cancer care for the whole patient: meeting psychosocial health needs. National Academies Press (US), Washington (DC)
8.
Newell S, Sanson-Fisher RW, Girgis A, Ackland S (1999) The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. Eur J Cancer Care (Engl) 8(2):73–82CrossRefPubMed
9.
Ping Ni, Jingli C, Na L (2010) Sample size estimation for quantitative studies in nursing studies. Chin J Nurs 45(4):378–380
10.
Shim EJ, Lee KS, Park JH et al (2011) Comprehensive needs assessment tool in cancer (CNAT): the development and validation. Support Care Cancer 19(12):1957–1968CrossRefPubMed
11.
Shin DW, Park JH, ShimEJ. et al (2011) The development of a Comprehensive Needs Assessment Tool for cancer-caregivers inpatient-caregiver dyads. Psychooncology 20(12):1342–1352CrossRefPubMed
12.
Xinshuang Z, Loling Z, Transozhen Li (2017) Sinicization and reliability validity test of the comprehensive needs assessment scale of cancer patients. Chin J Nurs 52(1):34–39
13.
Jing S, Wen Y, Xiaoling W (2018) Comprehensive needs survey and analysis of elderly cancer patients. J Nurs 33(20):82–85
14.
Hongwei S, Huaxia L, Yanchao J et al (2012) Progress in the physical and mental effects of religious psychological response on cancer patients and related factors. Nurs Res 26(17):1542–1544
15.
Ailan C, Hairong W (2019) Research status of the supportive care needs of colorectal cancer patients in China. Chin Drug Clin 19(24):4282–4283
16.
Baililan CJ (2021) New exploration, new challenges of-and adverse effects related to immune checkpoint inhibitor treatment. Chin J Cancer Biol Ther 28(05):419–430
17.
18.
Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345–361CrossRefPubMed
19.
Zhou X, Yao Z, Bai H et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22(9):1265–1274CrossRefPubMed
20.
Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270–1271CrossRefPubMed
21.
Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):1–28CrossRefPubMedPubMedCentral
22.
Jing Y, Yang J, Johnson DB et al (2022) Harnessing big data to characterize immune-related adverse events. Nat Rev Clin On-col 19(4):269–280CrossRef
23.
Qian Z, Ruixiang C, Jin W et al (2022) Meta-analysis of the association with efficacy of immune-related adverse effects in NSCLC with NSCIs. Pharm China 33(6):745–752
Metadaten
Titel
Investigation and analysis of the comprehensive unmet needs of cancer patients treated with immune checkpoint inhibitors: a cross-sectional study
verfasst von
Xiaoyan Luo
Renshan Cui
Ningning Zhang
Haiying Jiang
li Zhou
Xue Wang
Publikationsdatum
01.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-07911-3

Weitere Artikel der Ausgabe 8/2023

Supportive Care in Cancer 8/2023 Zur Ausgabe

Comment

Immersive virtual reality and neurofeedback for the management of cancer symptoms during treatment

Research

Telehealth palliative care interventions for patients with advanced cancer: a scoping review

Research

Do cancer centres and palliative care wards routinely measure patients’ quality of life? An international cross-sectional survey study

Research

Comorbidity burden and health-related quality of life in men with advanced prostate cancer

Research

Surviving cancer following total laryngectomy: a phenomenological study

Research

The effect of physical and psychological symptoms on spiritual well-being and emotional distress in inpatient cancer patients

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise